Elevai's hair and scalp solutions combine the power of Exosomes with advanced Mitochondrial Technology. The Elevai S-series Root Renewal System™ and the technology behind it will be presented at The Aesthetic Show on June 28th, 2024, held at the Wynn Las Vegas, NV. The Y100 mitochondrial technology was identified using Yuva's advanced artificial intelligence ("AI") platform, "MitoGPT" which was co-developed by Yuva Biosciences's Chief Scientific Officer, Keshav K. Singh, PhD and key advisor for AI, Jeb Lint ...

Elevai Biosciences Inc., an Elevai Labs company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.elevaibio.com. Forward-Looking Statements Statements contained in this press release regarding matters ...

NEWPORT BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced that Chief Executive Officer Jordan R. Plews, PhD has been invited back and will be presenting at the Beauty Through Science conference in Stockholm, Sweden on Thursday May 30, 2024. Beauty Through Science (BTS) is an annual event that gathers the greatest minds in aesthetic medicine to share the most up-to-date, innovative techniques and tec ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41875 | ELEVAI LABS INC. | | --- | (Exact name of registrant as specified in its charter) | Delaware | | 85-1399981 | | --- | --- | --- | | (State of incorporati ...

Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD)1.Elevai believes that EL-22 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass.Elevai plans to submit an Investigatio ...

Elevai Labs established two subsidiaries: Elevai Biosciences, Inc., and Elevai Skincare, Inc.Elevai Biosciences will focus on acquiring and developing biopharmaceutical technologies with initial focus on the development of EL-22 and EL-32, the lead assets targeting indications associated with obesity.Elevai Skincare will continue commercializing exosome skincare technologies for the medical dispensed skincare market. NEWPORT BEACH, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ:ELAB) ("E ...

Five international distribution agreements signed to dateCumulative contracted minimum purchase requirements of $4.9M in the first five yearsUp to five additional international distribution agreements in discussion NEWPORT BEACH, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- ELEVAI Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a medical aesthetic company specializing in physician-dispensed skincare, announces significant strides in global distribution and highlights an overview of current agreements. El ...

Taiwan is ELEVAI's third Asian contract for exosomes distribution after adding the Philippines in August of 2023 and Vietnam in May 2023 Asia-Pacific represents a combined $13 Billion prestige skincare and luxury haircare market4,5Immediate access to 40 specialty hair treatment clinics and four (4) high-end medical aesthetic clinics NEWPORT BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC. (NASDAQ:ELAB) ("Elevai" or the "Company"), a medical aesthetic company specializing in physician-disp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ For the fiscal year ended December 31, 2023 Commission File Number: 001-41875 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ELEVAI LABS INC. (Exact name of registrant as specified in its charter) Delaware 85-1399981 (State or other jurisdictio ...

NEWPORT BEACH, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQ:ELAB) a medical aesthetic company specializing in physician-dispensed skin care, is proud to announce the launch of its online E-commerce portal. The new E-commerce portal serves as a business-to-business (B2B) extension of the Company's existing B2B relationship with physician dispensed providers currently offering ELEVAI products in the $19.7 billion global industry1. Through the Company's online platform, retail customer ...